Psy49 - Budgetary Impact of Orphan Drugs in the Catalan Healthcare Service

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2626
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Economic Impact of the End of the Market Exclusivity for Orphan Drugs

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Potential Impact of the Cancer Drugs Fund Reform on Orphan Cancers

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Psy60 - Orphan Versus Ultra-Orphan Drugs Prices in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Examining the Target Population of Orphan Drugs: Are Drugs Exceeding the Intended Purposes of the Orphan Drug Act?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy150 - Inequity of Orphan Drugs Prices in Europe

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Budgeting and Budgetary Control in the Ghana Health Service

Journal of Economics and International Finance
2019English

Mechanism of Coordinated Access to Orphan Drugs

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2012English

Reimbursement of Orphan Drugs in Belgium: What (Else) Matters?

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2014English

Psy147 - Availability and Reimbursement of Orphan Drugs in the Czech Republic

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy